- Business Wire•5 days ago
Akebia Therapeutics, Inc. , a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor , today announced the publication of a retrospective analysis indicating persistently greater mortality in dialysis-dependent chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponse .
- Insider Monkey•15 days ago
Akebia Therapeutics Inc (NASDAQ:AKBA) just gave word of the initiation of its pivotal trial in a second indication for its lead renal anemia candidate, Vadadustat. The company already has one trial running, which kicked off late 2015, in non-dialysis dependent patients with anemia related to chronic kidney disease. This second indication is for the same […]
- Zacks•15 days ago
Akebia Therapeutics (AKBA) has witnessed a significant price decline in the past four weeks, and it has lately seen negative earnings estimate revisions as well.
Akebia Therapeutics, Inc. (AKBA)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
|Bid||7.12 x 100|
|Day's Range||7.90 - 8.20|
|52wk Range||6.40 - 14.20|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-2.69|
|Avg Vol (3m)||222,773|
|Dividend & Yield||N/A (N/A)|